Knockdown of cht4 did not affect tumour development in the absence of trametinib, while blanks and mfs14 weakly affected tumour development (compare Fig. 3D to EV3F): RAP alone displayed 7% survival compared to RAP;cht4i (1%), RAP;blanksi (17%) and RAP;mfs14i (23%). This evidence concerns the gene LRPAP1 and neoplasm.